Journal of Pancreatology (Dec 2018)

Gastroenteropancreatic neuroendocrine tumor registry study in China

  • Lin Cong, MD,
  • Wenming Wu, MD,
  • Wenhui Lou, MD,
  • Jinwan Wang, MD,
  • Feng Gu, MD,
  • Jiaming Qian, MD,
  • Jianming Xu, MD,
  • Feng Bi, MD,
  • Sanjun Cai, MD,
  • Chengwei Tang, MD,
  • Yulong He, MD,
  • Jie Zhong, MD,
  • Yupei Zhao, MD

DOI
https://doi.org/10.1097/JP9.0000000000000005
Journal volume & issue
Vol. 1, no. 1
pp. 35 – 38

Abstract

Read online

Abstract. Objectives:. The aim of this multicenter, prospective, registry study was to summarize the epidemiology of Chinese patients with locally advanced and end-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as well as the diagnostic methods and treatment strategies used for these patients. Methods:. GEP-NET patients from 11 departments of 8 hospitals in China were prospectively enrolled for a pre-defined period (June 30, 2011 to May 29, 2012). The patients’ demographic, pathological, and treatment data were recorded, analyzed, and released on June 29, 2015. Results:. Seventy-nine eligible patients were enrolled, and most of these patients were classified according to the World Health Organization 2010 classifications. The most common primary tumor site was the pancreas. The liver was the most common site of metastases, followed by the lymph nodes. The majority of the patients underwent surgical interventions. Patients also received local treatment, medication, or chemotherapy. Conclusion:. The pancreas was the most common primary tumor site of locally advanced and end-stage GEP-NETs. Surgical interventions are currently the most common treatment strategy.